The BRD8 antibody is a research tool designed to target the Bromodomain-containing protein 8 (BRD8), a member of the bromodomain and extra-terminal (BET) family. BRD8. also known as SMAP or PP9453. plays a role in chromatin remodeling and transcriptional regulation by recognizing acetylated lysine residues on histones through its bromodomain. It interacts with chromatin-modifying complexes, such as the SWI/SNF and NuA4/TIP60 complexes, influencing gene expression, DNA repair, and cell cycle progression. Dysregulation of BRD8 has been implicated in cancers, neurodevelopmental disorders, and viral infection responses.
BRD8 antibodies are widely used in studies to detect protein expression, localization, and function via techniques like Western blotting, immunofluorescence, immunoprecipitation, and chromatin immunoprecipitation (ChIP). These antibodies help elucidate BRD8's role in epigenetic mechanisms and disease pathways. Specific clones are validated for cross-reactivity, sensitivity, and application suitability, often involving knockout controls. Researchers also explore BRD8 as a potential therapeutic target, given the growing interest in BET inhibitors for cancer and inflammatory diseases. Its dual bromodomains and unique C-terminal regions distinguish BRD8 from other BET proteins, making selective antibody development critical for precise mechanistic studies.